New Medicines Globally
Every day, medicine access delays cost lives.
Medicine access. Made simple.
We are a registered medicines intermediary and international pharmacy and we are experts in patient access. We guide you and your physician to safely and legally access a prescription medicine that is not yet approved where you live.
Thousands of patients helped with information and access from 175 countries. Let us help you.
We have received enquiries from patients from all over the world. View our live map to see the countries we have supported with information and access to date.
Latest approved medicines available.
Obstructive Hypertrophic Cardiomyopathy | Camzyos (mavacamten) by Bristol-Myers Squibb - Approved by FDA April 2022.
PIK3CA-Related Overgrowth Spectrum (PROS) | Vijoice (alpelisib) by Novartis - Approved by FDA April 2022.
Recurrent Vulvovaginal Candidiasis| Vivjoa (oteseconazole) by Mycovia Pharmaceuticals - Approved by FDA April 2022.
Melanoma | Opdualag (nivolumab & relatlimab) by Bristol-Myers Squibb - Approved by FDA March 2022.
300% more doctors and patients requesting unapproved medicines to save lives
Latest clinical trials you can access
Help researchers make new medicines available to patients faster or benefit from a new treatment by taking part in clinical trials. See below the most recent clinical trials that you can join.
Evaluation of Parsaclisib plus Ruxolitinib in patients with Myelofibrosis who have not responded to Ruxolitinib alone
Evaluation of Tafasitamab plus Parsaclisib in patients with Non Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Leukemia or Lymphoma
Evaluation of Parsaclisib plus Rituximab or Obinutuzumab in patients with Lymphoma that has stopped responding to treatment
Evaluation of Tafasitamab plus Rituximab and Lenalidomide in patients with Lymphoma that has stopped responding to treatment